MIST’s CARDAMYST launch gains momentum on adoption and coverage
CARDAMYST’s launch is seeing strong adoption by electrophysiologists and positive payer coverage, with efforts shifting to cardiologist awareness. Revenue per script is expected to rise as coverage expands and free drug programs end.
Story updates
06:55:32 PM UTC
SquawkNews
CARDAMYST's launch shows strong early adoption by electrophysiologists and positive payer coverage. Efforts focus on expanding to cardiologists and boosting patient awareness. Revenue per script should rise as coverage grows and free drug programs taper. The pipeline includes a phase III AFib trial…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.